Company Analysis
Sign in

Cel-Sci Corporation (CVM)

NYSE: CVM · Biological Products, (No Diagnostic Substances) · Vienna, VA · filing with the SEC since 1996
Full chart Alerts Compare
Grade4.2
◀ Past 2.4● Present 4.3▶ Future 5.1
3 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Cel-Sci Corporation

Nine metrics read from its own filings, by tense
Headline grade
4.2/10
◀ Past2.425% of the headline
● Present4.335% of the headline
▶ Future5.140% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

2.4/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
1.7/10

Has it survived what it has been through?

7 warning events since 2017; the latest 2024-12-30.

weight 22% of this tense · 17th percentile among 159 sector filers · read for itself

From the record

Cel-Sci Corporation's filings since 2017 show 7 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 3 times, the latest 2018-07-13); a warning not to rely on past financial statements (8-K item 4.02, 3 times, the latest 2020-12-29); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2024-12-30) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
2.2/10

What has it actually done, year after year?

-34.9% a year over 4 filed years; profit years unseen.

weight 45% of this tense · 22nd percentile among 102 sector filers · read for its customers

From the record

Cel-Sci Corporation's 4 filed years say what it did: revenue went from $956 thousand in fiscal 2011 to $264 thousand in fiscal 2014, down 34.9% a year; it rose in 1 of 3 years; the deepest fall was 83% from fiscal 2011 to fiscal 2013 (its annual reports).

What it rests on

  • revenue growth over the filed span-34.9%bottom 6% of its family
  • the share of years revenue rosebottom 16% of its family
  • the deepest fall from a revenue peak83.3%bottom 44% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
3.2/10

How has it treated the people who own it?

SI estimate 3.2/10, confidence 35 of 100 (one part).

weight 33% of this tense · 32nd percentile among 146 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the bottom 32% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 146 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Cel-Sci Corporation's shareholder treatment is put at 3.2 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 32% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.3/1035% of the headline grade · 3 of 3 filed

Financial health

as filed
2.5/10

Is it financially healthy right now?

ROE -159%: lost 159¢ per shareholder dollar. Leverage 43%: owes 43¢ per asset dollar.

weight 45% of this tense · 25th percentile among 147 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-09-30, Cel-Sci Corporation lost about 159 cents for every dollar of shareholders' money. Leverage: it owed about 43 cents per dollar of assets, and net share issuance: its share count grew 125.1% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetsbottom 43% of its family
  • return on equitybottom 18% of its family
  • the share count against the year beforebottom 14% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
1.4/10

How strong is its position in its industry?

bottom 14% of 102 in its family.

weight 22% of this tense · 14th percentile among 102 sector filers · read for its customers

From the record

Cel-Sci Corporation's standing among 102 graded names in its industry family: revenue of $264 thousand in fiscal 2014 ranks in the bottom 13% by size; revenue growth of -34.9% a year over the last 3 filed years ranks in the bottom 15% (its annual reports).

What it rests on

  • revenue against the family$264,033bottom 13% of its family
  • three-year revenue growth-34.9%bottom 15% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed
8.6/10

What are the people in charge doing?

top 14% of 110 in its family for leadership; chief executive since 2017.

weight 33% of this tense · 86th percentile among 110 sector filers · read for its shareholders

From the record

Cel-Sci Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Kersten, Geert R (Chief Executive Officer, as filed), filing under that title since 2017-10-02, 9.1 years (top 12% of its family); the 6 officers and directors filing in the last fifteen months have been on the record a median of 20.9 years (top 1%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 6 people in charge now (top 30%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge2 in three years among 6 peopletop 30% of its family
  • the median years the people in charge have filed20.9 yearstop 1% of its family
  • the chief executive's years on the record9.1 yearstop 12% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

5.1/1040% of the headline grade · 1 of 3 filed, 2 estimated

Room to expand

SI estimate
3.5/10

How much room does it have to grow?

SI estimate 3.5/10, confidence 35 of 100 (one part).

weight 33% of this tense · 35th percentile among 152 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, cash less debt against assets, which ranks in the bottom 35% of 152 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
What the record cannot read
The record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
How it was reasoned
one part: cash less debt against assets, the one part on file, ranked among 152 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Cel-Sci Corporation's room to expand is put at 3.5 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the bottom 35% of 152 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.

Growth drivers

as filed
4.6/10

What could actually drive growth from here?

bottom 46% of 100 in its family for growth drivers.

weight 45% of this tense · 46th percentile among 100 sector filers · read for its customers

From the record

Cel-Sci Corporation's growth drivers, from the filed years to fiscal 2014: revenue grew -34.9% a year over the last three filed years against -34.9% over all 4, speeding up (top 36% of its family); the newest year grew 65.5% (top 25%); research spending grew -14.4% a year (bottom 22%); capital spending grew -60.9% a year (bottom 21%) (its annual reports). Cel-Sci Corporation tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth against the whole span+0.0 points a yeartop 36% of its family
  • the newest year's revenue growth65.5%top 25% of its family
  • three-year growth of research spending-14.4%bottom 22% of its family
  • three-year growth of capital spending-60.9%bottom 21% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate
8.8/10

Did its newest year beat what its own record pointed to?

SI estimate 8.8/10, confidence 35 of 100 (one part).

weight 22% of this tense · 88th percentile among 90 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, revenue against the prior three years' pace, which ranks in the top 12% of 90 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
What the record cannot read
The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned
one part: revenue against the prior three years' pace, the one part on file, ranked among 90 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Cel-Sci Corporation's expectations vs reality is put at 8.8 of 10 with a confidence of 35 of 100, because read from one part only, revenue against the prior three years' pace, which ranks in the top 12% of 90 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change. A filing that carries the missing parts replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton CVM · research, not advice